Potent oxindole based human beta3 adrenergic receptor agonists.
The synthesis and biological evaluation of a series of oxindole beta(3) adrenergic receptor agonists is described. A modulation of rat atrial tachycardia was observed with substitution at the 3-position of the oxindole moiety.
Stevens
F Craig
FC
Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Bloomquist
William E
WE
Borel
Anthony G
AG
Cohen
Marlene L
ML
Droste
Christine A
CA
Heiman
Mark L
ML
Kriauciunas
Aidas
A
Sall
Daniel J
DJ
Tinsley
Frank C
FC
Jesudason
Cynthia D
CD
D058667:Adrenergic beta-3 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D015394:Molecular Structure; D000078183:Oxindoles; D051381:Rats; D020318:Rats, Long-Evans; D022702:Receptors, Adrenergic, beta-3 / Q000096:biosynthesis / Q000235:genetics; D013610:Tachycardia / Q000188:drug therapy*
D058667:Adrenergic beta-3 Receptor Agonists; D000318:Adrenergic beta-Agonists; D007211:Indoles; D000078183:Oxindoles; D022702:Receptors, Adrenergic, beta-3; C022960:2-oxindole